Literature DB >> 23299919

Genetic and clinical specificity of 26 symptomatic carriers for dystrophinopathies at pediatric age.

Sandra Mercier1, Annick Toutain, Aurélie Toussaint, Martine Raynaud, Claire de Barace, Pascale Marcorelles, Laurent Pasquier, Martine Blayau, Caroline Espil, Philippe Parent, Hubert Journel, Leila Lazaro, Jon Andoni Urtizberea, Alexandre Moerman, Laurence Faivre, Bruno Eymard, Kim Maincent, Romain Gherardi, Denys Chaigne, Rabah Ben Yaou, France Leturcq, Jamel Chelly, Isabelle Desguerre.   

Abstract

The molecular basis underlying the clinical variability in symptomatic Duchenne muscular dystrophy (DMD) carriers are still to be precised. We report 26 cases of early symptomatic DMD carriers followed in the French neuromuscular network. Clinical presentation, muscular histological analysis and type of gene mutation, as well as X-chromosome inactivation (XCI) patterns using DNA extracted from peripheral blood or muscle are detailed. The initial symptoms were significant weakness (88%) or exercise intolerance (27%). Clinical severity varied from a Duchenne-like progression to a very mild Becker-like phenotype. Cardiac dysfunction was present in 19% of the cases. Cognitive impairment was worthy of notice, as 27% of the carriers are concerned. The muscular analysis was always contributive, revealing muscular dystrophy (83%), mosaic in immunostaining (81%) and dystrophin abnormalities in western blot analysis (84%). In all, 73% had exonic deletions or duplications and 27% had point mutations. XCI pattern was biased in 62% of the cases. In conclusion, we report the largest series of manifesting DMD carriers at pediatric age and show that exercise intolerance and cognitive impairment may reveal symptomatic DMD carriers. The complete histological and immunohistological study of the muscle is the key of the diagnosis leading to the dystrophin gene analysis. Our study shows also that cognitive impairment in symptomatic DMD carriers is associated with mutations in the distal part of the DMD gene. XCI study does not fully explain the mechanisms as well as the wide spectrum of clinical phenotype, though a clear correlation between the severity of the phenotype and inactivation bias was observed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23299919      PMCID: PMC3722679          DOI: 10.1038/ejhg.2012.269

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  42 in total

Review 1.  The epidemiology of mental retardation: challenges and opportunities in the new millennium.

Authors:  Helen Leonard; Xingyan Wen
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2002

2.  Symptomatic dystrophinopathies in female children.

Authors:  Natashia Seemann; Kathy Selby; Laura McAdam; Doug Biggar; Hanna Kolski; Sharan Goobie; Grace Yoon; Craig Campbell
Journal:  Neuromuscul Disord       Date:  2010-12-24       Impact factor: 4.296

3.  Pseudo-metabolic presentation in a Duchenne muscular dystrophy symptomatic carrier with 'de novo' duplication of dystrophin gene.

Authors:  N B Romero; P De Lonlay; S Llense; F Leturcq; G Touati; J A Urtizberea; J M Saudubray; A Munnich; J C Kaplan; D Récan
Journal:  Neuromuscul Disord       Date:  2001-07       Impact factor: 4.296

4.  Severe cognitive impairment in DMD: obvious clinical indication for Dp71 isoform point mutation screening.

Authors:  M P Moizard; A Toutain; D Fournier; F Berret; M Raynaud; C Billard; C Andres; C Moraine
Journal:  Eur J Hum Genet       Date:  2000-07       Impact factor: 4.246

5.  SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy.

Authors:  E Pegoraro; E P Hoffman; L Piva; B F Gavassini; S Cagnin; M Ermani; L Bello; G Soraru; B Pacchioni; M D Bonifati; G Lanfranchi; C Angelini; A Kesari; I Lee; H Gordish-Dressman; J M Devaney; C M McDonald
Journal:  Neurology       Date:  2010-12-22       Impact factor: 9.910

6.  Cardiac abnormalities and skeletal muscle weakness in carriers of Duchenne and Becker muscular dystrophies and controls.

Authors:  L Grain; M Cortina-Borja; C Forfar; D Hilton-Jones; J Hopkin; M Burch
Journal:  Neuromuscul Disord       Date:  2001-03       Impact factor: 4.296

7.  A female carrier of Duchenne muscular dystrophy complicated with cardiomyopathy.

Authors:  H Ogata; H Nakagawa; K Hamabe; A Hattori; Y Ishikawa; Y Ishikawa; M Saito; R Minami
Journal:  Intern Med       Date:  2000-01       Impact factor: 1.271

8.  Three cases of manifesting female carriers in patients with Duchenne muscular dystrophy.

Authors:  Tae-Jin Song; Kyung-A Lee; Seong-Woong Kang; Hanna Cho; Young-Chul Choi
Journal:  Yonsei Med J       Date:  2011-01       Impact factor: 2.759

Review 9.  The muscular dystrophies.

Authors:  Alan E H Emery
Journal:  Lancet       Date:  2002-02-23       Impact factor: 79.321

10.  Comprehensive detection of genomic duplications and deletions in the DMD gene, by use of multiplex amplifiable probe hybridization.

Authors:  Stefan White; Margot Kalf; Qiang Liu; Michel Villerius; Dieuwke Engelsma; Marjolein Kriek; Ellen Vollebregt; Bert Bakker; Gert-Jan B van Ommen; Martijn H Breuning; Johan T den Dunnen
Journal:  Am J Hum Genet       Date:  2002-07-08       Impact factor: 11.025

View more
  11 in total

Review 1.  Outside in: The matrix as a modifier of muscular dystrophy.

Authors:  Mattia Quattrocelli; Melissa J Spencer; Elizabeth M McNally
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2016-12-21       Impact factor: 4.739

Review 2.  Determining the role of skewed X-chromosome inactivation in developing muscle symptoms in carriers of Duchenne muscular dystrophy.

Authors:  Emanuela Viggiano; Manuela Ergoli; Esther Picillo; Luisa Politano
Journal:  Hum Genet       Date:  2016-04-21       Impact factor: 4.132

3.  Clinical and genetic characteristics of female dystrophinopathy carriers.

Authors:  Jingzi Zhong; Yanshu Xie; Vidata Bhandari; Gang Chen; Yiwu Dang; Haixia Liao; Jiapeng Zhang; Dan Lan
Journal:  Mol Med Rep       Date:  2019-02-25       Impact factor: 2.952

4.  In vivo cerebellar circuit function is disrupted in an mdx mouse model of Duchenne muscular dystrophy.

Authors:  Trace L Stay; Lauren N Miterko; Marife Arancillo; Tao Lin; Roy V Sillitoe
Journal:  Dis Model Mech       Date:  2019-12-09       Impact factor: 5.758

5.  Characteristics of disease progression and genetic correlation in ambulatory Iranian boys with Duchenne muscular dystrophy.

Authors:  Gholamreza Zamani; Sareh Hosseinpour; Mahmoud Reza Ashrafi; Mahmoud Mohammadi; Reza Shervin Badv; Ali Reza Tavasoli; Masood Ghahvechi Akbari; Ali Hosseini Bereshneh; Reza Azizi Malamiri; Morteza Heidari
Journal:  BMC Neurol       Date:  2022-05-02       Impact factor: 2.903

6.  DMD/BMD prenatal diagnosis and treatment expectation in a single centre in China for 15 years.

Authors:  Xingjian Zhong; Siying Cui; Lina Liu; Yuxia Yang; Xiangdong Kong
Journal:  BMC Med Genomics       Date:  2021-07-08       Impact factor: 3.063

7.  Diagnosis of late-onset Pompe disease and other muscle disorders by next-generation sequencing.

Authors:  Sébastien Lévesque; Christiane Auray-Blais; Elaine Gravel; Michel Boutin; Laura Dempsey-Nunez; Pierre-Etienne Jacques; Sébastien Chenier; Sandrine Larue; Marie-France Rioux; Walla Al-Hertani; Amelie Nadeau; Jean Mathieu; Bruno Maranda; Valérie Désilets; Paula J Waters; Joan Keutzer; Stephanie Austin; Priya Kishnani
Journal:  Orphanet J Rare Dis       Date:  2016-01-25       Impact factor: 4.123

8.  Serum Levels of MicroRNA-206 and Novel Mini-STR Assays for Carrier Detection in Duchenne Muscular Dystrophy.

Authors:  Mónica Alejandra Anaya-Segura; Héctor Rangel-Villalobos; Gabriela Martínez-Cortés; Benjamín Gómez-Díaz; Ramón Mauricio Coral-Vázquez; Edgar Oswaldo Zamora-González; Silvia García; Luz Berenice López-Hernández
Journal:  Int J Mol Sci       Date:  2016-08-13       Impact factor: 5.923

9.  Connexin-43 reduction prevents muscle defects in a mouse model of manifesting Duchenne muscular dystrophy female carriers.

Authors:  Julie Nouet; Eric Himelman; Kevin C Lahey; Qingshi Zhao; Diego Fraidenraich
Journal:  Sci Rep       Date:  2020-03-30       Impact factor: 4.379

10.  Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up.

Authors:  Amir Dori; Michela Guglieri; Marianna Scutifero; Luigia Passamano; Antonio Trabacca; Luisa Politano
Journal:  Acta Myol       Date:  2021-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.